ArticleAnnals of hematology2026
Outcome of initial cord blood transplantation with FM80TBI as conditioning regimen for acute myeloid leukemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Outcomes of allogeneic stem cell transplantation in older patients with acute myeloid leukemia (AML) have been unsatisfactory. At our center, cord blood transplantation (CBT) using FM80TBI has been implemented in older patients or those with comorbidities. We conducted a retrospective single-center study to evaluate transplantation outcomes in patients with AML who underwent CBT following FM80TBI. The FM80TBI regimen consisted of fludarabine (125 or 150 mg/m²), melphalan (80 mg/m²), and total-body irradiation (4 Gy). This study included 58 patients. The median follow-up period was 38 months. The median age at transplant was 67 (52–73) years. At the time of CBT, 39.7% of all patients having an Eastern Cooperative Oncology Group performance status of ≤ 2 did not achieve complete remission (CR), 25.9% had adverse cytogenetic risk, and 53.4% were positive for Wilms tumor gene-1 messenger RNA in peripheral blood. Neutrophil engraftment by day 42 was achieved in 87.9% of patients. The 3-year overall survival (OS) was 67.1%, the 3-year non-relapse mortality was 14.4%, and the 3-year cumulative incidence of relapse was 20.0%. Patients with CR status at the time of CBT had significantly better 3-year OS than those with non-CR status (86.8% vs. 42.4%, P < 0.05). The cumulative incidences of Grade II–IV acute graft-versus-host disease (GVHD) at day 100 and chronic GVHD at 2 years were 29.4% and 15.0%, respectively. Although this was a single-center retrospective study, the outcomes of CBT for older patients with AML or those with comorbidities following FM80TBI were favorable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.